Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Erenumab→

Erenumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1582205-90-0
Molecular formula
Not available
Molecular weight
Not available
Drug class
Calcitonin gene-related peptide (CGRP) receptor antagonisthuman monoclonal antibody
Mechanism of action
Binds the CGRP receptor and antagonises CGRP-receptor signalling, inhibiting a pathway involved in migraine pathophysiology.
Indications / reported uses
  • Preventive treatment of migraine in adults; not indicated for acute treatment of migraine attacks

Sources: US DailyMed — AIMOVIG (erenumab-aooe) · EMA EPAR — Aimovig · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Erenumab Environmental Risk Assessment (ERA) (the Erenumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.